Epidemiology of chemotherapy-related adverse drug reactions among patients with cancer in Ethiopia: A systematic review and meta-analysis.

IF 0.9 4区 医学 Q4 ONCOLOGY
Woretaw Sisay Zewdu, Samuel Berihun Dagnew, Mulugeta Molla Zeleke, Yared Andargie Ferede, Achenef Bogale Kassie, Muluken Adela Alemu, Tilay Arega Moges
{"title":"Epidemiology of chemotherapy-related adverse drug reactions among patients with cancer in Ethiopia: A systematic review and meta-analysis.","authors":"Woretaw Sisay Zewdu, Samuel Berihun Dagnew, Mulugeta Molla Zeleke, Yared Andargie Ferede, Achenef Bogale Kassie, Muluken Adela Alemu, Tilay Arega Moges","doi":"10.1177/10781552251372165","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveAdverse drug reaction (ADR) induces iatrogenic harm, costs a lot in cancer care continuum. However, there is a dearth of concrete evidence regarding its prevalence in a resource-limited setting. Thus, the present systematic review set out to cohere the available evidences.Designsystematic review and meta-analysis.Data sourcesPubMed, CINAHL, Web of Science, EMBASE, and Google Scholar databases were searched.Eligibility criteriaobservational studies focused on the magnitude of chemotherapy-related ADRs among patients with cancer were eligible.Data extraction and synthesisPrimary studies quality was appraised employing the Joanna Briggs Institute (JBI) Checklist. A random-effects meta-analysis employing the meta package for proportions (Metaprop) was conducted. Heterogeneity was assessed with Cochrane's Q test and <i>I</i><sup>2</sup> statistic, and publication bias with Egger's test and a funnel plot. Protocol was registered at PROSPERO with a reference number - [CRD42024546390].ResultsOut of 1507 identified studies, 7 were met the inclusion criteria. The pooled prevalence of ADRs was 43% [95% CI: 35%, 50%, <i>I</i><sup>2</sup> = 87.06%]. Age > 65 years (<i>p</i> = 0.001), standard anticancer dose (<i>p</i> = 0.015), concomitant medication (<i>p</i> < 0.000), etoposide (<i>p</i> < 0.002), mercaptopurine (<i>p</i> < 0.041), doxorubicin (<i>p</i> < 0.005) and polychemotherapy (<i>p</i> < 0.001) were the predictors of chemotherapy-related ADRs.ConclusionChemotherapy-related ADRs are quite common among patient with cancer in Ethiopia. Consequently, healthcare providers should pay closer attention to ADR assessment and monitoring by using tailored screening tools, with special emphasis on older adults, those receiving standard anticancer doses, concomitant medications, polychemotherapy, or regimens containing etoposide, mercaptopurine, or doxorubicin to improve safety and efficacy of chemotherapies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251372165"},"PeriodicalIF":0.9000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552251372165","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ObjectiveAdverse drug reaction (ADR) induces iatrogenic harm, costs a lot in cancer care continuum. However, there is a dearth of concrete evidence regarding its prevalence in a resource-limited setting. Thus, the present systematic review set out to cohere the available evidences.Designsystematic review and meta-analysis.Data sourcesPubMed, CINAHL, Web of Science, EMBASE, and Google Scholar databases were searched.Eligibility criteriaobservational studies focused on the magnitude of chemotherapy-related ADRs among patients with cancer were eligible.Data extraction and synthesisPrimary studies quality was appraised employing the Joanna Briggs Institute (JBI) Checklist. A random-effects meta-analysis employing the meta package for proportions (Metaprop) was conducted. Heterogeneity was assessed with Cochrane's Q test and I2 statistic, and publication bias with Egger's test and a funnel plot. Protocol was registered at PROSPERO with a reference number - [CRD42024546390].ResultsOut of 1507 identified studies, 7 were met the inclusion criteria. The pooled prevalence of ADRs was 43% [95% CI: 35%, 50%, I2 = 87.06%]. Age > 65 years (p = 0.001), standard anticancer dose (p = 0.015), concomitant medication (p < 0.000), etoposide (p < 0.002), mercaptopurine (p < 0.041), doxorubicin (p < 0.005) and polychemotherapy (p < 0.001) were the predictors of chemotherapy-related ADRs.ConclusionChemotherapy-related ADRs are quite common among patient with cancer in Ethiopia. Consequently, healthcare providers should pay closer attention to ADR assessment and monitoring by using tailored screening tools, with special emphasis on older adults, those receiving standard anticancer doses, concomitant medications, polychemotherapy, or regimens containing etoposide, mercaptopurine, or doxorubicin to improve safety and efficacy of chemotherapies.

埃塞俄比亚癌症患者化疗相关药物不良反应的流行病学:系统回顾和荟萃分析。
目的:药物不良反应(ADR)是一种医源性危害,在肿瘤治疗过程中花费巨大。然而,在资源有限的情况下,缺乏具体的证据证明其普遍存在。因此,本系统综述旨在整合现有证据。设计系统评价和荟萃分析。检索了pubmed、CINAHL、Web of Science、EMBASE和谷歌Scholar数据库。资格标准:关注癌症患者化疗相关不良反应程度的观察性研究符合资格。数据提取和综合采用乔安娜布里格斯研究所(JBI)检查表对初步研究质量进行评价。随机效应荟萃分析采用比例荟萃包(Metaprop)进行。异质性评价采用Cochrane’s Q检验和I2统计量,发表偏倚评价采用Egger’s检验和漏斗图。协议在PROSPERO注册,参考编号为[CRD42024546390]。结果1507项纳入研究中,7项符合纳入标准。不良反应总发生率为43% [95% CI: 35%, 50%, I2 = 87.06%]。年龄0 ~ 65岁(p = 0.001),标准抗癌剂量(p = 0.015),伴随用药(p p p p p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信